Florida-based private equity firm Accelmed Partners closed its second fund at its hard cap of $400 million, with a unique focus on lower middle market healthcare technology companies that have seen strong growth despite the challenges of the coronavirus pandemic.
Accelmed Fund II exceeded its original $300 million target and has already put money to work in TearLab and NeuroPace. TearLab is an ocular surface diagnostics company for dry eye disease that was acquired by Accelmed in July 2020. Developer of brain technology for individuals suffering from neurological disorders, Neuropace, saw Accelmed lead a $67 million . . .
Unlock this article instantly, along with the rest of our premium content, newsletters and data tables tracking investor and manager activity. Monthly and annual subs available.